CompletedPhase 2NCT03070392

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Studying Uveal melanoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Immunocore Ltd
Principal Investigator: Immunocore Medical Information
Immunocore Ltd
Intervention: IMCgp100(biological)
Enrollment: 378 target
Eligibility: 18-99 years · All sexes
Timeline: 2017 – 2025

Study locations (30)

UCLA Medical Center, Los Angeles, California, United States
The Angeles Clinic and Research Institute, Los Angeles, California, United States
Byers Eye Institute, Stanford University, Palo Alto, California, United States
California Pacific Medical Center, San Francisco, California, United States
University of Colorado, Aurora, Colorado, United States
University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
The University of Chicago Medicine, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Columbia University Medical Center, New York, New York, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03070392 on ClinicalTrials.gov

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

See all trials for Uveal melanoma →

← Back to all trials